



Diagnostics to Pathogenomics of
**Sexually Transmitted
Infections**

Edited by
Sunit K. Singh

WILEY Blackwell

**Diagnostics to Pathogenomics
of Sexually Transmitted Infections**

Diagnostics to Pathogenomics of Sexually Transmitted Infections

Edited by Sunit K. Singh, PhD

*Professor of Molecular Immunology
Head, Molecular Biology Unit
Professor Incharge-Centre of Experimental Medicine & Surgery
Faculty of Medicine
Institute of Medical Sciences (IMS)
Banaras Hindu University (BHU), Varanasi, India*

WILEY Blackwell

This edition first published 2019
© 2019 John Wiley & Sons Ltd

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

The right of Sunit K Singh to be identified as the author of the editorial material in this work has been asserted in accordance with law.

Registered Office

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA

Editorial Office

The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

Limit of Liability/Disclaimer of Warranty

While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Library of Congress Cataloging-in-Publication Data

Names: Singh, Sunit K., editor.

Title: Diagnostics to pathogenomics of sexually transmitted infections /edited by, Sunit K. Singh.

Description: Hoboken, NJ : Wiley Blackwell, 2018. | Includes bibliographical references and index. |

Identifiers: LCCN 2018024559 (print) | LCCN 2018024972 (ebook) | ISBN9781119380900

(Adobe PDF) | ISBN 9781119380955 (ePub) | ISBN 9781119380849 (hardcover)

Subjects: | MESH: Sexually Transmitted Diseases

Classification: LCC RC200 (ebook) | LCC RC200 (print) | NLM WC 140 | DDC616.95/1–dc23

LC record available at <https://lcn.loc.gov/2018024559>

Cover Design: Wiley

Cover Image: © mathagraphics/Shutterstock

Set in 10/12pt Warnock by SPi Global, Pondicherry, India

Contents

About the Editor *xv*

Contributors *xvii*

Preface *xxi*

- 1 Mucosal Immunity in Sexually Transmitted Infections** *1*
Jiri Mestecky and Michael W. Russell
- 1.1 Introduction *1*
- 1.2 Innate Immunity in the Genital Tract *2*
- 1.2.1 Humoral Defense Factors in Female Secretions *2*
- 1.2.2 Innate Defense Factors in the Male Tract *4*
- 1.3 Immunoglobulins in Secretions of the Genital Tract *4*
- 1.3.1 Female Genital Tract Secretions *4*
- 1.3.2 Origin of Igs in Human Genital Tract Secretions *7*
- 1.3.3 Functions of Genital Tract Antibodies *8*
- 1.4 Cells of the Mucosal Immune System of the Genital Tract *10*
- 1.4.1 Epithelial Cells *10*
- 1.4.2 Immunoglobulin-Producing Cells *10*
- 1.4.3 T Cells and Other Cell Types *11*
- 1.5 Induction of Immune Responses in the Genital Tract *12*
- 1.5.1 Induction of Humoral Immune Responses in Human Male Genital Tract Secretions *14*
- 1.5.2 Immune Responses in the Genital Tract after Infections *15*
- 1.5.2.1 Gonorrhea *15*
- 1.5.2.2 Chlamydia *15*
- 1.5.2.3 Human Immunodeficiency Virus (HIV) *16*
- 1.5.2.4 Human Papilloma Virus *16*
- 1.6 Concluding Remarks *17*
- References *17*
- 2 The Role of Circumcision in Preventing Sexually Transmitted Infections** *27*
Kouros Afshar, Behnam Kazemi, and Andrew E. MacNeily
- 2.1 Introduction *27*
- 2.2 Biological Mechanisms *27*
- 2.3 Methods of Circumcision *28*

2.4	Complications	28
2.5	Role of MC in Transmission of HIV	29
2.5.1	Male-to-Female Transmission	29
2.5.2	Female-to-Male Transmission	29
2.5.3	Male-to-Male Transmission	30
2.6	Human Papilloma Virus (HPV)	30
2.7	Nonulcerative STIs	31
2.7.1	Gonorrhea	31
2.7.2	<i>Trichomonas Vaginalis</i> (Tv)	32
2.7.3	Chlamydia Trachomatis (Ct)	32
2.8	Ulcerative STIs/Genital Ulcer Disease (GUD)	32
2.8.1	Syphilis	33
2.8.2	Chancroid	34
2.9	Use of Male Circumcision as a Public Health Measure	34
2.10	Female Genital Mutilation (FGM)	35
	References	36
3	Effect of Probiotics on Reproductive Health	41
	<i>Piotr Kochan, Magdalena Strus, and Piotr B. Heczko</i>	
3.1	Introduction	41
3.2	Definition of Probiotics	43
3.3	Vaginal Microflora (Microbiota)	46
3.4	Applications of Probiotics in Vaginal and Reproductive Health	49
3.4.1	Vaginitis (Aerobic Vaginitis (AV), Bacterial Vaginosis (BV), and Vulvovaginal Candidiasis (VVC))	50
3.4.2	UTI	52
3.4.3	Pregnancy	52
3.4.4	Other Obstetrics and Gynecology (OB/GYN) Uses of Probiotics	53
3.5	Conclusions	53
	References	54
4	Human Immunodeficiency Virus (HIV) Infection	61
	<i>Santosh Kumar Singh and Sunit K. Singh</i>	
4.1	Introduction	61
4.2	HIV Structure/Genome	62
4.3	Routes of Transmission	64
4.3.1	Sexual Transmission	64
4.3.1.1	STDs and Sexual Transmission of HIV	64
4.3.1.2	Vulnerability of Female Genital Tract for HIV Transmission	66
4.3.2	Transmission by Contaminated Blood/Blood Product Transfusion	68
4.3.3	Transmission by Sharing Syringe and Needles	68
4.3.4	Transmission from Mother to Fetus or Newborn Babies	68
4.3.5	Occupational Risk in Healthcare Workers	68
4.4	Host Factors Influencing HIV Infectivity in Sexual Transmission	69
4.4.1	Systemic Host Factors	69
4.4.2	Local Host Factors	69
4.5	Viral Factors Influencing HIV Infectivity in Sexual Transmission	70

4.6	Mechanism of Pathogenesis	71
4.7	Diagnosis of HIV Infections	72
4.8	Therapeutics	73
4.8.1	Antiretroviral Therapies (ARTs)	73
4.8.2	Combinational ARTs	74
4.9	Conclusion	74
	References	75
5	Genital Herpes	83
	<i>Andreas Sauerbrei</i>	
5.1	Introduction	83
5.2	Pathogen	83
5.3	Epidemiology	84
5.4	Pathogenesis and Immunity	84
5.5	Clinical Features	86
5.6	Diagnosis	87
5.7	Treatment	90
5.8	Prevention and Control	93
5.9	Conclusion	94
	References	95
6	Molluscum Contagiosum	101
	<i>Tugba Kevser Uzuncakmak and Ayse Serap Karadag</i>	
6.1	Introduction	101
6.2	Epidemiology	101
6.3	Molecular Pathogenesis	102
6.4	Diagnosis	103
6.5	Clinical Features	106
6.6	Mode of Spread of Infections	107
6.7	Treatment	107
6.7.1	Treatment Options	108
6.7.1.1	Watchful Waiting	108
6.7.1.2	Procedure-Based Treatments	109
6.7.1.3	Chemical Agents	110
6.7.1.4	Immune Modulators	111
6.7.1.5	Antiviral Agents	112
6.7.1.6	Immunocompromised Patients	112
6.8	Conclusion	113
	References	113
7	Genital Warts	119
	<i>Filip Rob</i>	
7.1	Introduction	119
7.2	Human Papillomavirus	119
7.2.1	Taxonomy	119
7.2.2	Life Cycle	120
7.2.3	Interaction with Immune System	120

7.2.4	Transmission	120
7.2.5	Clearance	120
7.3	Epidemiology	121
7.4	Risk and Protective Factors	121
7.4.1	Risk Factors	121
7.4.2	Protective Factors	122
7.5	Clinical Features	122
7.5.1	Physical Signs	122
7.5.2	Symptoms	123
7.6	Diagnostics	124
7.6.1	Clinical Investigation	124
7.6.2	3–5% Acetic Acid	124
7.6.3	Histopathology	124
7.6.4	HPV DNA Detection	125
7.6.5	HPV Antibodies	125
7.7	Differential Diagnosis	125
7.8	Treatment	126
7.8.1	Cryotherapy	126
7.8.2	Laser Therapy (CO ₂ laser, Er:YAG laser)	127
7.8.3	Electrocautery	127
7.8.4	Surgical Excision	127
7.8.5	Trichloroacetic Acid (80–90% solution)	127
7.8.6	Podophyllotoxin (0.05% solution or 0.15% gel)	127
7.8.7	Imiquimod (3.75% or 5% cream)	127
7.8.8	Sinecatechins (10% or 15% ointment)	129
7.9	Specific Groups	129
7.9.1	Immunocompromised Patients	129
7.9.2	Pregnant Women	129
7.9.3	Children	129
7.10	HPV Vaccination	130
	References	131

8 Chlamydia Trachomatis Urogenital Infections: Epidemiology, Clinical Presentations, and Pathogenesis 135

Charles W. Armitage, Alison J. Carey, Danica K. Hickey, and Kenneth W. Beagley

8.1	Introduction	135
8.2	Epidemiology	135
8.3	Chlamydial Biology	136
8.3.1	The Attachment and Entry of Chlamydial EBs	136
8.3.2	The Chlamydial Inclusion	137
8.3.3	Chlamydial Replication and Persistence	137
8.4	Clinical Features	138
8.4.1	Urogenital Tract Infections	139
8.4.2	Female Urogenital Tract	139
8.4.3	Infection and Pregnancy	141
8.4.4	Male Urogenital Tract	142
8.4.5	Anorectal Tract Infections	143

8.4.6	Gastrointestinal Chlamydial Infections and Persistence	144
8.4.7	Lymphogranuloma Venereum	144
8.5	Pathogenesis of Chlamydial Infections	145
8.5.1	Pathogenesis of Female Genital Tract Chlamydial Infections	145
8.5.2	Lower FRT Pathogenesis	146
8.5.3	Upper FRT Pathogenesis	146
8.5.4	Pathogenesis of Male Urogenital Tract	148
8.5.5	Chlamydial Urethritis and Prostatitis	148
8.5.6	Chlamydial Infections of the Upper MRT	148
8.5.7	Chlamydial Epididymitis	149
8.5.8	Chlamydial Orchitis	149
8.6	Diagnosis and Treatment	150
8.7	Prevention and Control	151
8.8	Conclusion	152
	References	153
9	Donovanosis	167
	<i>Sarita Martins De Carvalho Bezerra, Marcio Martins Lobo Jardim, and Juliana Uchiyama</i>	
9.1	Introduction	167
9.2	Epidemiology	168
9.3	Pathology	168
9.4	Incubation Period	169
9.5	Clinical Pictures	170
9.6	Sites of Involvement	174
9.7	Complications and Sequelae	175
9.8	Diagnosis	175
9.9	Differential Diagnosis	176
9.10	Treatment	176
9.11	Prevention and Control	177
9.12	Disease Control and Prevention	178
	References	178
10	Gonorrhoea	181
	<i>María Teresa Pérez-Gracia and Beatriz Suay-García</i>	
10.1	Introduction	181
10.2	Pathogen	182
10.2.1	Morphology	182
10.2.2	Virulence Factors	183
10.2.2.1	Type IV Pili (Tfp)	183
10.2.2.2	Por Proteins	183
10.2.2.3	Opacity Proteins (Opa)	184
10.2.2.4	Rmp Proteins	184
10.2.2.5	Lipooligosaccharide (LOS)	184
10.2.2.6	IgA Protease	185
10.2.3	Physiology	185
10.2.4	Genome	185

10.3	Pathogenesis and Immunity	185
10.4	Epidemiology	186
10.5	Clinical Features	188
10.5.1	Gonococcal Infection in Men	188
10.5.2	Gonococcal Infection in Women	188
10.5.3	Extragenital Locations	188
10.6	Diagnosis	189
10.6.1	Samples	189
10.6.2	Staining	191
10.6.3	Culture	191
10.6.4	Identification	193
10.6.5	<i>Neisseria gonorrhoeae</i> Genotyping	193
10.6.6	Nucleic Acid Amplification Tests (NAATs)	197
10.7	Treatment	198
10.8	Prevention and Control	200
10.9	Conclusion	202
	References	202
11	Sexually Transmitted Treponematoses	211
	<i>Lenka Mikalová and David Šmajš</i>	
11.1	Introduction	211
11.2	Genetics of TPA and TEN Strains	212
11.3	Virulence Factors of Syphilis and Bejel	214
11.4	Diagnostics of Syphilis and Bejel	215
11.5	Treatment of Syphilis and Bejel	217
11.6	Molecular Typing of Syphilis and Bejel Treponemes	220
11.7	Vaccine Development for Syphilis and Bejel	222
	References	223
12	Genital Mycoplasmas	233
	<i>Suncanica Ljubin-Sternak</i>	
12.1	Introduction	233
12.2	Biology	234
12.3	Pathogenesis	235
12.3.1	Adhesion Proteins	236
12.3.2	Antigenic Variation	236
12.3.3	Production of Enzymes	236
12.3.4	Facultative Intracellular Localization	237
12.3.5	Capacity to Induce Host Immune Response	237
12.4	Epidemiology	237
12.5	Clinical Presentation	238
12.5.1	Urogenital Infections in Women	238
12.5.1.1	Bacterial Vaginosis	238
12.5.1.2	Cervicitis	239
12.5.1.3	Pelvic Inflammatory Disease (PID) and Its Sequelae	239
12.5.1.4	Infections in Pregnancy	240

- 12.5.2 Urogenital Infections in Men 241
 - 12.5.2.1 Nongonococcal Urethritis (NGU) 241
 - 12.5.2.2 Epididymitis and Prostatitis 241
 - 12.5.2.3 Infertility 241
- 12.5.3 Rare Manifestations and Clinical Features in Immunocompromised Persons 242
 - 12.5.3.1 Urinary Calculi 242
 - 12.5.3.2 Systemic Infection and Arthritis 242
 - 12.5.3.3 Infection in Immunocompromised Patients 242
- 12.6 Laboratory Diagnosis 243
 - 12.6.1 Specimen Collection 243
 - 12.6.2 Culture Methods 243
 - 12.6.3 Molecular Methods 245
 - 12.6.4 Serology 246
- 12.7 Treatment 247
- 12.8 Prevention and Control 248
- References 249

13 Bacterial Vaginosis 257

Aliona Rosca and Nuno Cerca

- 13.1 Introduction 257
- 13.2 Implication of *G. vaginalis* in Bacterial Vaginosis 258
- 13.3 Epidemiology and Risk Factors 260
- 13.4 Pathogenesis and Immunity 261
- 13.5 Clinical Features 263
- 13.6 Diagnosis 263
- 13.7 Treatment 266
- 13.8 Conclusions 268
- References 268

14 Chancroid 277

Margaret E. Bauer and Diane M. Janowicz

- 14.1 Introduction 277
- 14.2 Epidemiology of Chancroid and *H. ducreyi* 277
- 14.3 Clinical Features 278
- 14.4 The Pathogen 279
- 14.5 Pathogenesis and Immunity 280
 - 14.5.1 Overview of Pathogenesis 280
 - 14.5.2 Virulence Mechanisms 280
 - 14.5.3 Regulation of Virulence 282
 - 14.5.4 Immune Response 283
- 14.6 Diagnosis, Treatment, and Prevention 284
- 14.7 Chronic Limb Ulcers Caused by *H. ducreyi* 285
- 14.8 Conclusions 286
- References 287

15	Vulvovaginal Candidosis	293
	<i>Gilbert G.G. Donders, Katerina S. Ruban, Gert Bellen, and Sivtrigaile Grinceviciene</i>	
15.1	Introduction	293
15.2	Etiology	293
15.2.1	Pathogens	293
15.2.2	Morphology	294
15.3	Epidemiology	294
15.3.1	Prevalence	294
15.3.1.1	Asymptomatic Colonization	294
15.3.1.2	Symptomatic Infection	295
15.3.2	Risk Factors	298
15.3.3	Sexual Transmission	298
15.3.4	Young and Elderly Women	298
15.4	Pathogenesis and Immunity	300
15.4.1	Hormones	300
15.4.2	Pregnancy	300
15.4.3	Impaired Glucose Tolerance	301
15.4.4	Genetic Predisposition	301
15.4.4.1	STAT1 Gain of Function Mutations	302
15.4.4.2	CARD9	302
15.4.4.3	AIRE Mutation	302
15.4.4.4	NALP3/CIAS1	304
15.4.4.5	Interleukin-4	304
15.4.4.6	Dectin-1	304
15.4.4.7	Mannose-Binding Lectin (MBL)	304
15.4.5	Other Factors Affecting Pathogenesis	305
15.5	Symptoms and Signs	305
15.5.1	Acute/Episodic Infection	305
15.5.2	Recurrent Vulvovaginal Candidosis	306
15.6	Diagnosis and Differential Diagnosis	306
15.6.1	Clinical Signs	306
15.6.2	Clinical Examination	306
15.6.3	Wet Mount Microscopy	307
15.6.4	Vaginal pH	309
15.6.5	Vaginal Mycological Culture	310
15.6.6	Molecular Biology	310
15.6.7	Histology	310
15.6.8	Differential Diagnosis	310
15.7	Treatment	311
15.7.1	General Principles of Treatment	311
15.7.2	Treatment of Uncomplicated Acute Infection	311
15.7.3	Treatment of Complicated Acute Infection	312
15.7.3.1	Severe Symptoms, <i>C. albicans</i> Vulvovaginitis	314
15.7.3.2	Non- <i>Albicans</i> Candida Infection	314
15.7.3.3	Poorly Controlled Diabetes, Immune Suppression	315
15.7.3.4	Pregnancy and Breastfeeding	315

15.7.4	Recurrent Vulvovaginal Candidiasis (RVVC)	316
15.7.4.1	Azole-Resistant <i>C. albicans</i>	317
15.7.4.2	Elimination of Risk Factors of Recurrence in RVVC Patients	317
15.7.4.3	Underlying Reasons for Failing Maintenance Therapy	318
	References	319
16	Tinea Cruris	329
	<i>Anuradha Bishnoi and Rahul Mahajan</i>	
16.1	Introduction	329
16.2	Etiology and Epidemiology	330
16.3	Tinea Cruris as a Sexually Transmitted Infection (STI)	331
16.4	Transmission	331
16.5	Pathogenesis	332
16.5.1	Environmental Factors	332
16.5.2	Agent Factors	332
16.5.3	Host Factors	332
16.5.4	Host Immune Response	333
16.5.5	Clinical Features	333
16.5.6	Variants	335
16.5.6.1	Tinea incognito	335
16.5.6.2	Vesico-Bullous Tinea Cruris	335
16.5.6.3	White Paint Dots and Pseudomembranous Tinea	335
16.6	Differential Diagnoses	336
16.6.1	Candidiasis	336
16.6.2	Erythrasma	336
16.6.3	Hyperpigmented Pityriasis Versicolor	336
16.7	Laboratory Diagnosis	336
16.7.1	Direct Examination	336
16.7.2	Culture	337
16.7.3	Nucleic Acid Amplification Tests	337
16.8	Treatment of Tinea Cruris and Genitalis	337
16.8.1	Topicals	337
16.8.2	Systemic	337
16.8.3	Recalcitrant/Resistant Tinea: Pathomechanisms and Treatment	338
16.8.4	General Measures to Prevent Tinea Cruris	338
16.9	Conclusion	338
	Acknowledgments	339
	References	339
17	Trichomonas Vaginalis	341
	<i>Barbara Van Der Pol</i>	
17.1	Introduction	341
17.2	Epidemiology of <i>T. vaginalis</i>	342
17.3	HIV and Trichomonas	344
17.4	Biology and Pathogenesis of <i>T. vaginalis</i>	345
17.5	Clinical Features of <i>T. vaginalis</i> Infection	346
17.6	Diagnosis of <i>T. vaginalis</i>	348